The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous studies have demonstrated the therapeutic effects of CB2 agonists in a large range of disease models, including Alzheimer’s disease”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Rentsch et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“As PD progresses dopamine availability decreases, leading to the characteristic locomotor deficits including tremors, rigidity and bradykinesia (Chaudhuri et al., 2006).”
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 2×
“Jo ur na l P re -p ro of While CB2 selective agonists have not been investigated, they could be of particular clinical relevance, as it is suggested that targeting this receptor does not provoke the psychoactive side-effects associated with CB1 receptor activation (Pacher et al., 2006).”
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“…activation of astrocytes (Liddelow et al., 2017), that there are unique subsets of glia with only a proportion impacting neurodegenerative diseases (Deczkowska et al., 2018; Jordão et al., 2019; Keren-Shaul et al., 2017; Masuda et al., 2019) and that immediate activation and proliferation of…”
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution
Masuda, T., Sankowski, R., Staszewski, O., Böttcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S., Kunz, P., van Loo, G., et al. (2019) · Nature · doi:10.1038/s41586-019-0924-x · Cited by 1,310
Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation
Jordão, M. J. C., Sankowski, R., Brendecke, S. M., Sagar, Locatelli, G., Tai, Y.-H., Tay, T. L., Schramm, E., Armbruster, S., Hagemeyer, N., et al. (2019) · Science · doi:10.1126/science.aat7554 · Cited by 843 · cited 1×
“, 2017), that there are unique subsets of glia with only a proportion impacting neurodegenerative diseases (Deczkowska et al., 2018; Jordão et al., 2019; Keren-Shaul et al., 2017; Masuda et al., 2019) and that immediate activation and proliferation of microglia after neuronal injury may favour recovery (Tay et al.”
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis
Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633
A new fate mapping system reveals context-dependent random or clonal expansion of microglia
Tay, T. L., Mai, D., Dautzenberg, J., Fernández-Klett, F., Lin, G., Sagar, Datta, M., Drougard, A., Stempfl, T., Ardura-Fabregat, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4547 · Cited by 597
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522
Self-citation
Research works printed but not linked: 62
- Andersson, 1999, Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal Prodynorphin mRNA in a rat model of Parkinson’s disease, Neurobiol. Dis., 6, 461, 10.1006/nbdi.1999.0259 · DOI · Paper page
- Ashton, 2007, The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration, Curr. Neuropharmacol., 5, 73, 10.2174/157015907780866884 · DOI · Paper page
- Benito, 2003, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains, J. Neurosci., 23, 11136, 10.1523/JNEUROSCI.23-35-11136.2003 · DOI · Paper page
- Benito, 2008, Cannabinoid CB2 receptors in human brain inflammation, Br. J. Pharmacol., 153, 277, 10.1038/sj.bjp.0707505 · DOI · Paper page
- Bisogno, 2010, Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders, CNS Neurol. Disord. Drug Targets, 9, 564, 10.2174/187152710793361568 · DOI · Paper page
- Blanpied, 2005, Amantadine inhibits NMDA receptors by accelerating channel closure during channel block, J. Neurosci., 25, 3312, 10.1523/JNEUROSCI.4262-04.2005 · DOI · Paper page
- Brigham, 2018, Pharmacokinetic/pharmacodynamic correlation analysis of amantadine for levodopa-induced dyskinesia, J. Pharmacol. Exp. Ther., 367, 373, 10.1124/jpet.118.247650 · DOI
- Buckley, 2000, Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor, Eur. J. Pharmacol., 396, 141, 10.1016/S0014-2999(00)00211-9 · DOI · Paper page
- Cenci, 2007, Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice, Curr. Protoc. Neurosci. Chapter 9, Unit, 9, 25
- Danysz, 1997, Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies, Neurosci. Biobehav. Rev., 21, 455, 10.1016/S0149-7634(96)00037-1 · DOI · Paper page
- Di Marzo, 2018, New approaches and challenges to targeting the endocannabinoid system, Nat. Rev. Drug Discov., 17, 623, 10.1038/nrd.2018.115 · DOI · Paper page
- Doo, 2014, Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model, BMC Complement. Altern. Med., 14, 107, 10.1186/1472-6882-14-107 · DOI
- dos-Santos-Pereira, 2016, Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action, Neurobiol. Dis., 94, 179, 10.1016/j.nbd.2016.06.013 · DOI
- Fasano, 2010, Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia, Proc. Natl. Acad. Sci. U. S. A., 107, 21824, 10.1073/pnas.1012071107 · DOI
- Fernández-Trapero, 2017, Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis, Dis. Model. Mech., 10, 551
- Ferrer, 2003, Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias, Eur. J. Neurosci., 18, 1607, 10.1046/j.1460-9568.2003.02896.x · DOI
- Fieblinger, 2014, Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia, Nat. Commun., 5, 5316, 10.1038/ncomms6316 · DOI · Paper page
- Finseth, 2015, Self-reported efficacy of Cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evidence-Based Complement, Altern. Med., 1
- Fox, 2002, Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease, Mov. Disord., 17, 1180, 10.1002/mds.10289 · DOI · Paper page
- Girasole, 2018, A subpopulation of striatal neurons mediates levodopa-induced dyskinesia, Neuron, 97, 787, 10.1016/j.neuron.2018.01.017 · DOI
- Gómez-Gálvez, 2016, Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson’s disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatr., 64, 200, 10.1016/j.pnpbp.2015.03.017 · DOI · Paper page
- Gundersen, 1987, The efficiency of systematic sampling in stereology and its prediction, J. Microsc., 147, 229, 10.1111/j.1365-2818.1987.tb02837.x · DOI · Paper page
- Hanus, 1999, HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor, Proc. Natl. Acad. Sci. U. S. A., 96, 14228, 10.1073/pnas.96.25.14228 · DOI · Paper page
- Javed, 2016, Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s disease, Front. Neurosci., 10, 321, 10.3389/fnins.2016.00321 · DOI · Paper page
- Jordan, 2019, Progress in brain cannabinoid CB2 receptor research: from genes to behavior, Neurosci. Biobehav. Rev., 98, 208, 10.1016/j.neubiorev.2018.12.026 · DOI · Paper page
- Keren-Shaul, 2017, A unique microglia type associated with restricting development of Alzheimer’s disease, Cell, 169, 1276, 10.1016/j.cell.2017.05.018 · DOI · Paper page
- Khakh, 2015, Diversity of astrocyte functions and phenotypes in neural circuits, Nat. Neurosci., 18, 942, 10.1038/nn.4043 · DOI · Paper page
- Kim, 2015, Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission, J. Physiol., 593, 871, 10.1113/jphysiol.2014.286633 · DOI
- Kim, 2012, Microglia-inhibiting activity of Parkinson’s disease drug amantadine, Neurobiol. Aging, 33, 2145, 10.1016/j.neurobiolaging.2011.08.011 · DOI
- Li, 2016, Deletion of CB2 cannabinoid receptors reduces synaptic transmission and long-term potentiation in the mouse hippocampus, Hippocampus, 26, 275, 10.1002/hipo.22558 · DOI
- Lotan, 2014, Cannabis (Medical Marijuana) treatment for motor and non–motor symptoms of Parkinson disease, Clin. Neuropharmacol., 37, 41, 10.1097/WNF.0000000000000016 · DOI · Paper page
- Lundblad, 2004, A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function, Neurobiol. Dis., 16, 110, 10.1016/j.nbd.2004.01.007 · DOI · Paper page
- MacCallum, 2018, Practical considerations in medical cannabis administration and dosing, Eur. J. Intern. Med., 49, 12, 10.1016/j.ejim.2018.01.004 · DOI · Paper page
- Manson, 2012, Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life, J. Park. Dis., 2, 189
- Martinez, 2012, The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats, Neurosci. Res., 72, 236, 10.1016/j.neures.2011.12.006 · DOI
- Morgese, 2007, Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB1 and TRPV1 receptors, Exp. Neurol., 208, 110, 10.1016/j.expneurol.2007.07.021 · DOI · Paper page
- Mulas, 2016, Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson’s disease, Exp. Neurol., 286, 83, 10.1016/j.expneurol.2016.09.013 · DOI
- Ossola, 2011, Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected], Neuropharmacology, 61, 574, 10.1016/j.neuropharm.2011.04.030 · DOI
- Pandey, 2017, Levodopa-induced dyskinesia: clinical features, pathophysiology, and medical management, Ann. Indian Acad. Neurol., 20, 190, 10.4103/aian.AIAN_239_17 · DOI
- Paquette, 2012, Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA vs. 5-HT1A receptors, Eur. J. Neurosci., 36, 3224, 10.1111/j.1460-9568.2012.08243.x · DOI
- Pavón, 2006, ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in Hemiparkinsonian mice, Biol. Psychiatry, 59, 64, 10.1016/j.biopsych.2005.05.044 · DOI · Paper page
- Perez-Lloret, 2018, Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia, J. Neural Transm., 125, 1237, 10.1007/s00702-018-1869-1 · DOI
- Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease, Eur. J. Neurosci., 29, 2177, 10.1111/j.1460-9568.2009.06764.x · DOI · Paper page
- Priller, 2019, Targeting microglia in brain disorders, Science (80-), 365, 32, 10.1126/science.aau9100 · DOI
- Rentsch, 2019, Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia, BMC Neurosci., 20, 5, 10.1186/s12868-019-0487-7 · DOI
- Schallert, 2000, CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury, Neuropharmacology, 39, 777, 10.1016/S0028-3908(00)00005-8 · DOI · Paper page
- Schuler, 2009, Optimized surgical techniques and postoperative care improve survival rates and permit accurate telemetric recording in exercising mice, BMC Vet. Res., 5, 28, 10.1186/1746-6148-5-28 · DOI
- Sebastianutto, 2016, Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists, Neurobiol. Dis., 96, 156, 10.1016/j.nbd.2016.09.001 · DOI
- Sharma, 2018, Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease, Ther. Clin. Risk Manag., 14, 665, 10.2147/TCRM.S144481 · DOI
- Smith, 2012, Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia, Behav. Brain Res., 226, 281, 10.1016/j.bbr.2011.09.025 · DOI
- Song, 2014, The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats, Drug Des. Devel. Ther., 8, 2173
- Stayte, 2015, Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson’s disease, PLoS One, 10, 10.1371/journal.pone.0124325 · DOI
- Stayte, 2017, Activin A inhibits MPTP and LPS-induced increases in inflammatory cell populations and loss of dopamine neurons in the mouse midbrain in vivo, PLoS One, 12, 10.1371/journal.pone.0167211 · DOI
- Suárez, 2014, L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice, Biol. Psychiatry, 75, 711, 10.1016/j.biopsych.2013.05.006 · DOI · Paper page
- Tay, 2018, Unique microglia recovery population revealed by single-cell RNAseq following neurodegeneration, Acta Neuropathol. Commun, 6, 87, 10.1186/s40478-018-0584-3 · DOI
- Thiele, 2012, Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson’s disease, J. Vis. Exp., 1
- Thiele, 2014, Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models, Neurobiol. Dis., 71, 334, 10.1016/j.nbd.2014.08.006 · DOI
- Thorlund, 2012, Stability of additive treatment effects in multiple treatment comparison meta-analysis: a simulation study, Clin. Epidemiol., 4, 75
- Venderová, 2004, Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms, Mov. Disord., 19, 1102, 10.1002/mds.20111 · DOI · Paper page
- Walsh, 2010, The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats, Brain Res., 1363, 40, 10.1016/j.brainres.2010.09.086 · DOI
- Winkler, 2002, L-DOPA-induced dyskinesia in the Intrastriatal 6-hydroxydopamine model of Parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function, Neurobiol. Dis., 10, 165, 10.1006/nbdi.2002.0499 · DOI · Paper page
- Zhang, 2013, Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses, J. Neurosci., 33, 11655, 10.1523/JNEUROSCI.0288-13.2013 · DOI
Cited by
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Self-citation
Metadata
- Authors
- Rentsch, P., Stayte, S., Egan, T., Clark, I., & Vissel, B.
- ORCID
- Stayte, Sandy
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 134
- Pages
- 104646
- ISSN
- 0969-9961
- Cited by
- 37
- References
- 15
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Parkinson's NSW
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia. https://app.cochat.ai/papers/10.1016/j.nbd.2019.104646
- The paper
- Rentsch, P., Stayte, S., Egan, T., Clark, I., & Vissel, B. (2020). Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2019.104646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.